Posted by Michael Wonder on 02 Dec 2022
FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation
1 December 2022 - Today, the FDA approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation as detected by an FDA approved test.
Today, the FDA also approved the Abbott RealTime IDH1 Assay to select patients for olutasidenib.
